Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5658088 | 0.99 | HTR1A (0.49) | HTR1AHTR2ATMEM97KCNH2ACHE | |
| SCHEMBL5661218 | 0.90 | KCNH2 (0.52) | HTR1AHTR2ATMEM97KCNH2ACHE | |
| SCHEMBL5661060 | 0.88 | HTR1A (0.53) | HTR1AHTR2ATMEM97KCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL5658805 | 0.87 | KCNH2 (0.54) | HTR1AHTR2ATMEM97KCNH2DRD2 | |
| SCHEMBL5659017 | 0.86 | ACHE (0.53) | HTR1AHTR2ATMEM97KCNH2ACHE | |
| SCHEMBL5249199 | 0.85 | ACHE (0.51) | HTR1AHTR2ATMEM97KCNH2ACHE | |
| Fumaric Acid SCHEMBL5661544 | 0.84 | HTR1A (0.51) | HTR1AHTR2ATMEM97KCNH2ACHE | |
| Fumaric Acid SCHEMBL5661539 | 0.84 | HTR1A (0.51) | HTR1AHTR2ATMEM97KCNH2ACHE | |
| SCHEMBL5658875 | 0.83 | HTR1A (0.52) | HTR1AHTR2ATMEM97ACHEDRD2 | |
| SCHEMBL5251963 | 0.82 | HTR2C (0.54) | HTR1AHTR2ATMEM97ACHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 79/4885HTR2A 153/4885TMEM97 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.